News & Updates

The leading cause of disease burden and death across the globe is still cardiovascular disease (CVD), with low, low-middle, and middle sociodemographic index (SDI) regions carrying the heaviest burden, according to a study.

In the phase III ICONIC-LEAD trial, selective blockade of the interleukin(IL)-23 receptor with the targeted oral peptide icotrokinra is associated with higher rates of skin clearance and symptom relief in adults and adolescents with moderate-to-severe plaque psoriasis.

A 70-year-old male was diagnosed with prostate cancer (PC) after presenting with increased urinary frequency and an elevated prostate-specific antigen (PSA) level of 71 ng/mL in October 2022. (Figure) MRI revealed a 3 cm left prostatic lesion without pelvic lymph node involvement or bone metastases, with possible extra­prostatic extension and seminal vesicle invasion. Transperineal ultrasound-guided prostate biopsy confirmed prostatic ade­nocarcinoma in 8 out of 12 cores, with a Gleason score of 4 + 3.